Emerging treatments
Clinical trials
Ongoing treatment trials focus on patients with smoldering myeloma. Major challenges for trials designed to target patients with precursor disease include the need for future therapies to be low risk for the individual patient and, at the same time, offer some meaningful benefit.
Markers of progression
Although almost all MGUS patients remain stable, there are no markers or clinical findings at diagnosis to determine whether a specific patient is at risk of progression to multiple myeloma and related malignancies. There is a need to better define high-risk MGUS versus low-risk MGUS, based on reliable molecular markers. With better markers and the development of newer, less toxic drugs, it may be possible to delay MGUS progression to malignancy.
Use of this content is subject to our disclaimer